Global Blood has sights on FDA accelerated approval with sickle cell drug data
The company presented updated data for the drug, voxelotor, at the European Hematology Association conference in Amsterdam Friday.
The company presented updated data for the drug, voxelotor, at the European Hematology Association conference in Amsterdam Friday.
On Saturday, the company will present a poster of Phase I trial data for belantamab mafodotin, which targets the same antigen, BCMA, as Amgen bispecific antibody AMG 420 and multiple CAR-T cell therapies in development.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In a phone interview, CEO Jakob Lindberg indicated that data so far showed a study was doing well in terms of progression-free survival.